JSKN022 not checked

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“JSKN022 administered intravenously at selected dose levels according to protocol”In the company’s words, NCT07292402 on ClinicalTrials.gov
Tested for
Advanced Malignant Solid Tumors
Main trialPhase 1
“The goal of this clinical trial is to learn if drug JSKN022 is safe to treat patients with advanced malignant solid tumors. It will also learn about the pharmacokinetic/ pharmacodynamic profiles and preliminary antitumor activity of drug JSKN022.”In the company’s words, NCT07292402 on ClinicalTrials.gov

Other drugs for Advanced Malignant Solid Tumors

All 2440 drugs for Advanced Malignant Solid Tumors

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 31 Aug 2027 JSKN022 in Subjects With Advanced Malignant Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow JSKN022

Following is part of Solo: you see every change to JSKN022 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in